💊 Zydus Lifesciences: The Retest Before the Run? 🔁🚀

Zydus is knocking at a critical resistance zone (~₹1025) — a level that previously acted as a launchpad and then turned into a ceiling. Now, after a classic mean-reversion to 200 EMA and a healthy base-building phase, the stock is showing signs of strength again. 🧬 Technical Highlights: 🔄 Price reclaiming ₹1000 zone after major correction 🟣 Strong support at 200 EMA (₹849) 📈 A breakout above ₹1025 could open up higher levels 📦 What Could Fuel the Move? Strong pipeline across generics, biosimilars, and vaccines Consistent earnings delivery despite global pharma headwinds India’s healthcare focus = long-term structural tailwinds 🎯 Watch Out For: Breakout + Volume Confirmation above ₹1025 = 🔓 breakout trade Targets? ₹1200–₹1350+ range over coming quarters if momentum builds Once resistance is conquered, it often turns into powerful support. Let’s see if Zydus is ready to heal its chart too! 💉📈